

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Oliver SCHADT et al.

Serial No.: 10/552,064

Group Art Unit: 1609

Filed: October 5, 2005

Examiner: JARRELL, Noble E.

Title: SUBSTITUTED PYRAZOLE COMPOUNDS

**SUPPLEMENTAL REPLY**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SIR:

Further to the Reply filed on February 26, 2008, please consider the following.

Applicants in support of arguments in the last Reply cited and provided  
Polymorphism: in the pharmaceutical industry (edited by *Ralf Hilfiker*; 2006 Wiley-VCH),  
Chapter 8, The Importance of Solvates, by *U. J. Griesser*, pp. 211-222 (hereinafter *Griesser*).

Upon review it was discovered that said Chapter's last 11 pages were not provided to the USPTO. The submitted chapter extends from page 211 to page 233. The previously not submitted pages 223 to 233 are attached to this supplemental reply.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

/Csaba Henter/

---

Csaba Henter, Reg. No. 50,908  
Anthony J. Zelano, Reg. No. 27,969  
Attorneys for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza 1  
2200 Clarendon Boulevard, Suite 1400  
Arlington, VA 22201  
Direct Dial: 703-812-5331  
Facsimile: 703-243-6410  
Attorney Docket No.: MERCK-3067

Date: March 27, 2008

K:\Merck\3000 - 3999\3067\Suppl Reply Mar 08.doc